Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: A family study with part of the stanislas cohort

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 1, 1998, Pages 84-91

  Henry, M ^a   Tregouet D A ^b   Alessi, M C ^a   Aillaud, M F ^a   Visvikis, S ^c   Siest, G ^c   Tiret, L ^b   Juhan Vague, I ^a  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c Centre de Medecine Preventive   (France)

Author keywords

Genetics; Insulin resistance; Myocardial infarction; Plasminogen activator inhibitor 1; Risk factors

Indexed keywords

ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CHILD; FAMILY STUDY; FEMALE; FIBRINOLYSIS; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEX DIFFERENCE;

EID: 0031984392     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.1.84     Document Type: Article

References (10)

1. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1986;83:6776-6780.
2. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381-387.
3. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
4. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
5. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factor and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996;94:2057-2063.
6. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC study. Circulation. 1995;91:284-290.
7. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of insulin and acute-phase response. Arteriosclerosis. 1989;9:362-367.
8. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb. 1993;13:1865-1873.
9. Bavenholm P, Proudler A, Silveira A, Crook D, Blombäck M, de Faire U, Hamsten A. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb Haemost. 1995;73:568-575.
10. Me Gill JD, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.